Publikationen

2018

Rinaldetti S, Wirtz R, Worst TS, Hartmann A, Breyer J, Dyrskjot L, Erben P. FOXM1 predicts disease progression in non-muscle invasive bladder cancer. J Cancer Res Clin Oncol. 2018 Sep;144(9):1701-1709. doi: 10.1007/s00432-018-2694-5. Epub 2018 Jun 29.

2018

Baur V, Papadopoulos T, Kazakov DV, Agaimy A, Hartmann A, Isbary G, Wirtz RM, Schultz ES. A case of multiple familial trichoepitheliomas responding to treatment with the Hedgehog signaling pathway inhibitor vismodegib. Virchows Arch. 2018 Jun 22. doi: 10.1007/s00428-018-2397-y

2018

Zinnall U, Weyerer V, Compérat E, Camparo P, Gaisa NT, Knuechel-Clarke R, Perren A, Lugli A, Toma M, Baretton G, Kristiansen G, Wirtz RM, Cheng L, Wullich B, Stoehr R, Hartmann A, Bertz S. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype. Hum Pathol. 2018 Jun 6. pii: S0046-8177(18)30190-4. doi: 10.1016/j.humpath.2018.05.022.

2018

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P. A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

2018

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2.

2018

Schmidt M, Weyer-Elberich V, Hengstler JG, Heimes AS, Almstedt K, Gerhold-Ay A, Lebrecht A, Battista MJ, Hasenburg A, Sahin U, Kalogeras KT, Kellokumpu-Lehtinen PL, Fountzilas G, Wirtz RM, Joensuu H. Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Res. 2018 Feb 26;20(1):15. doi: 10.1186/s13058-018-0942-x.

2018

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P. Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. Transl Oncol. 2018 Apr;11(2):467-476. doi: 10.1016/j.tranon.2018.02.001. Epub 2018 Feb 23.

2018

Legler K, Rosprim R, Karius T, Eylmann K, Rossberg M, Wirtz RM, Müller V, Witzel I, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L. Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer. Br J Cancer. 2018 Mar 20;118(6):847-856. doi: 10.1038/bjc.2017.472. Epub 2018 Jan 30.

2018

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17.

2017

Erber R, Stöhr R, Herlein S, Giedl C, Rieker RJ, Fuchs F, Ficker JH, Hartmann A, Veltrup E, Wirtz RM, Brueckl WM. Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer. Anticancer Res. 2017 Dec;37(12):6771-6778.

2017

Kaemmerer D, Sänger J, Arsenic R, D'Haese JG, Neumann J, Schmitt-Graeff A, Wirtz RM, Schulz S, Lupp A. Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas. Oncotarget. 2017 Sep 23;8(52):89958-89969. doi: 10.18632/oncotarget.21194. eCollection 2017 Oct 27.

2017

Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A. Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget. 2017 Jun 28;8(40):67684-67695. doi: 10.18632/oncotarget.18804. eCollection 2017 Sep 15.

2017

Erben P, Wezel F, Wirtz R, Martini T, Stein D, Weis CA, Hartmann A, Bolenz C. [Role of the human ErbB family receptors in urothelial carcinoma of the bladder: mRNA expression status and prognostic relevance]. Aktuelle Urol. 2017 Aug;48(4):356-362. doi: 10.1055/s-0043-110403. Epub 2017 Jul 27. German.

2017

Timotheadou E, Kalogeras KT, Koliou GA, Wirtz RM, Zagouri F, Koutras A, Veltrup E, Christodoulou C, Pentheroudakis G, Tsiftsoglou A, Papakostas P, Aravantinos G, Venizelos V, Pectasides D, Kosmidis P, Karanikiotis C, Markopoulos C, Gogas H, Fountzilas G. Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Transl Oncol. 2017 Aug;10(4):589-598. doi: 10.1016/j.tranon.2017.05.006. Epub 2017 Jun 27.

2017

Stefanovic S, Wirtz RM, Deutsch TM, Hartkopf A, Sinn P, Varga Z, Sobottka B, Sotiris L, Taran FA, DomschkeC, HennigsA, Brucker SY, Sohn C, Schuetz F, Schneeweiss A, Wallwiener M. Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. Oncotarget, Advance Publications 2017

2017

Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P. FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. Oncotarget. 2017 Apr 24. doi: 10.18632/oncotarget.17394. [Epub ahead of print]

2017

Cohen SA, Yu M, Baker K, Redman M, Wu C, Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula V, Kalogeras KT, Fountzilas G, Grady WM. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases. Clin Epigenetics. 2017 May 2;9:46. doi: 10.1186/s13148-017-0347-1. eCollection 2017.

2017

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W.. High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. Transl Oncol. 2017 Mar 22;10(3):340-345.

2017

Brückl WM, Wirtz RM, Bertsch T, Ficker JH, Jung A. [Liquid Biopsy: Detection of Molecular Markers for Treatment Decisions in Lung Cancer]. Pneumologie. 2017 Mar;71(3):151-163. doi: 10.1055/s-0042-123803. Epub 2017 Feb 14. Review. German.

 

2017

 

Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Koutras A, Lazaridis G, Christodoulou C, Pentheroudakis G, Economopoulou P, Laskarakis A, Arapantoni-Dadioti P, Batistatou A, Sotiropoulou M, Aravantinos G, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. J Transl Med. 2017 Feb 13;15(1):30.

2017

Sinn HP, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, Lakis S, Veltrup E, Altevogt P, Eidt S, Wirtz RM, Marmé F. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer. 2017 Feb 13;17(1):124.

2017

Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; on behalf of the BRIDGE Consortium. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch. 2017 Jan 10. doi: 10.1007/s00428-017-2064-8

2016

Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium..ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.Urol Int. 2016 Dec 17.

2016

Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P. Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.. Anticancer Res. 2016 Oct;36(10):5205-5213.

2016

Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W. ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). Virchows Arch. 2016 Nov;469(5):547-552.

2016

Kripp M, Merx K, Wirtz RM, Gaiser T, Eidt S, Schwaab J, Post S, Wenz F, Hochhaus A, Hofheinz RD, Erben P. Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer. Gastroenterol Res Pract. 2016;2016:3481578.

2016

Laible M, Schlombs K, Kaiser K, Veltrup E, Herlein S, Lakis S, Stöhr R, Eidt S, Hartmann A, Wirtz RM, Sahin U. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2016 Jul 7;16:398.

2016

Neubauer E, Wirtz RM, Kaemmerer D, Athelogou M, Schmidt L, Sänger J, Lupp A. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects. Oncotarget. 2016 Jul 5;7(27):41959-41973.

2016

Wirtz RM, Sihto H, Isola J, Heikkilä P, Kellokumpu-Lehtinen PL, Auvinen P, Turpeenniemi-Hujanen T, Jyrkkiö S, Lakis S, Schlombs K, Laible M, Weber S, Eidt S, Sahin U, Joensuu H. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast Cancer Res Treat. 2016 Jun;157(3):437-46. doi: 10.1007/s10549-016-3835-7.

2016

Wirtz RM, Fritz V, Stöhr R, Hartmann A. Molecular classification of bladder cancer. Possible similarities to breast cancer. Pathologe. 2016 Feb;37(1):52-60. doi: 10.1007/s00292-015-0134-8. German.

2015

Linardou H, Kalogeras KT, Kronenwett R, Alexopoulou Z, Wirtz RM, Zagouri F, Scopa CD, Gogas H, Petraki K, Christodoulou C, Pavlakis K, Koutras AK, Samantas E, Patsea H, Pectasides D, Bafaloukos D, Fountzilas G.Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. Anticancer Res. 2015 Jul;35(7):4023-36.

2015

Benderska N, Dittrich AL, Knaup S, Rau TT, Neufert C, Wach S, Fahlbusch FB, Rauh M, Wirtz RM, Agaimy A, Srinivasan S, Mahadevan V, Rümmele P, Rapti E, Gazouli M, Hartmann A, Schneider-Stock R. miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis. Inflamm Bowel Dis. 2015 Sep;21(9):2039-51.

2015

Brückl WM, Al-Batran SE, Ficker JH, Wirtz RM, Atmaca A.. Estrogen Receptors and their Impact for Prognosis and Therapy of Lung Cancer – New Insights to an Underestimated Mechanism. Pneumologie. 2015 Jun;69(6):350-60. doi: 10.1055/s-0034-1392081. Review. German.

2015

Koutras A, Kalogeras KT, Wirtz RM, Alexopoulou Z, Bobos M, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Pentheroudakis G, Pisanidis N, Magkou C, Christodoulou C, Bafaloukos D, Papakostas P, Aravantinos G, Pectasides D, Kalofonos HP, Fountzilas G.Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. J Transl Med. 2015 May 29;13:171.

2015

2015

2015

2015

Kaemmerer D, ReimannC, Specht E, Wirtz RM, Sayeg M, Baum RP, SchulzS, Lupp A. Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms. Oncotarget. 2015. Feb 20;6(5):3346-58.

2015

2014

Witzel I, Milde-Langosch K, Schmidt M, Karn T, Becker S, Wirtz R, Rody A, Laakmann E, Schütze D, Jänicke F, Müller V. Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. Onco Targets Ther. 2014 Nov 28;7:2205-13.

2014

2014

2013

2013

2013

2012

2012

2012

2012

Marme F, Schneeweiss A, Aigner J, Sohn C, Eidt S, Altevogt HP, Sinn P, Wirtz RM. Ki67 mRNA Einzelgenmessung prädiziert Ansprechen auf Chemotherapie. Senologie – Zeitschrift für Mammadiagnostik und -therapie 2012; 9 -A107.

2012

Aigner J, Schneeweiss A, Marme F, Sohn C, Eidt S, Altevogt HP, Sinn P, Wirtz RM. Molekulare Subtypisierung auf mRNA Basis prädiziert Therapieansprechen und Überleben nach neoajuvanter Chemotherapie. Senologie – Zeitschrift für Mammadiagnostik und -therapie 2012; 9 -A2.

2012

Wirtz RM, Marme F, Aigner J, Eidt S, Sohn C, Jaeger D, Altevogt HP, Sinn P, Schneeweiss A. Two-Gene-Ratio aus ESR1 und MMP7 als Prognoseparameter nach neoadjuvanter Chemotherapie (NACT). Senologie – Zeitschrift für Mammadiagnostik und -therapie 2012; 9 -A177.

2012

Sinn HP, Keller M, Waldburger N, Schneeweiss A, Wirtz R. Evaluation of tumor proliferation and hormone receptor status in breast cancer. Comparison of quantitative real time PCR, Image analysis of IHC, and visual scoring. Jahrestagung der Deutschen Gesellschaft für Pathologie 2012; SO-024.

2012

Wirtz RM, Bertz S, Keck B,Claas S, Dyrskjot L, Orntoft T, Wullich B, Hake R, Eidt S, Hartmann A. Prognostic role of androgen receptor in bladder cancer. Jahrestagung der Deutschen Gesellschaft für Pathologie 2012; SO-067.

2012

Knaup S, Wach S, Agalmy A, Schulze-Luehmann J, Hugele M, Chaklam S, Atreya R, Wirtz R, Tau TT, Schneider-Stock R. miRNA 26b stabilizes the pro-apoptotic DAP Kinase by inhibiting its E3 ubiquitine ligase DIP1.Jahrestagung der Deutschen Gesellschaft für Pathologie 2012; DO-115.

2012

2012

Gehoff A, Basten O, Sprenger T, Conradi LC, Bismarck C, Bandorski D, Merkelbach-Bruse S, Schneider-Stocl R, Stoehr R, Wirtz RM, Kitz J, Müller A, Hartmann A, Becker H, Ghadimi BM, Liersch T, Rüschoff J. Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression os a new and highly effivient method. Am J Surg Pathol. 2012 Feb; 36(2):202-13.

2012

2012

2012

2011

Wirtz R,  Leinonen M, Bono P, Isola J, Kellokumpu-Lehtinen PL, Kataja V, Turpeeniemi-Hujanen T, Jyrkkiö S, Huang W, Eidt S, Joensuu H. RACGAP1 mRNA assay outperforms Ki-67 as a proliferation marker in the FinHer study cohort. P02-12-04. SABCS 2011. 

2011

Huang W, Wirtz R, Weidler J, Lie Y, Sherwood T, Leinonen M, Bono P, Isola J, Kellokumpu-Lehtinen PL, Joensuu H. Quantitative measurements of HER2 protein expression and HER2 mRNA expression as continous variable in breast cancer of he FinHer study. P01-07-01. SABCS 2011.

2011

Wirtz R, Eidt S. Quantitative Bestimmung tumorinfiltrierender Lymphozyten mittels qRT-PCR in formalinfixierten Tumorgeweben zur Prädiktion von Brustkrebs – Immune STRATIFYER. Jahrestagung der Deutschen Gesellschaft für Senologie 2011.

2011

Wirtz R, Leinonen M, Eidt S, Joensuu H. Überlegenheit der molekularpathologischen Proliferatonsmessung gegenüber Ki67 Bestimmung zur Risikobeurteilung – Proliferation STRATIFYER. Jahrestagung der Deutschen Gesellschaft für Senologie 2011.

2011

Wirtz R, Riehm K, Hellmich M, Gevensleben H, Sinn P, Eidt S, Schmutzler R. BRCA1 Defizienztestung in triple negativen, luminalen und BRCA1 positiven Tumoren. Jahrestagung der Deutschen Gesellschaft für Senologie 2011.

2011

Wirtz R, Brueckl WM, Eschbach C, Wiest GH, Ficker JH, Zirlik S, Hake R, Eidt S, Hartmann A. Prognostische Bedeutung von ESR1, PGR und SNAIL2 mRNA Expression beim Nicht-kleinzelligen Bronchialkarzinom. Jahrestagung der Deutschen Gesellschaft für Pathologie 2011.

2011

Brueckl WM, Eschbach C, Wiest GH, Ficker JH, Zirlik S, Hake R, Eidt S, Hartmann A, Wirtz RM. Influence of expression of estrogen (ESR1) and progesterone (PGR) receptors on metastatic spread and outcome in non-small cell lung cancer (NSCLC). J Clin Oncol 29: 2011 (suppl: abstr 7585)

2011

Fountzilas E, Angouridakis N, Karasmanis I, Wirtz RM, Eleftheraki AG, Veltrup E, Markou K, Nikolaou A, Konstantinopoulos P, Kotoula V, Fountzilas G. Prediction of clinical outcome in patients with primary laryngeal carcinoma using gene expression profiling. J Clin Oncol 29: 2011 (suppl: abstr 5505)

2011

2011

2011

Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G.Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat. 2011 Feb; 126(1): 109-17. Epub2010 Dec 29.

2010

Ihnen M, Wirtz RM, Kalogeras KT, Milde-Langosch K, Schmidt M, Witzel I, Eleftheraki AG, Papadimitriou C, Jänicke F, Briassoulis E, Pectasides D, Rody A, Fountzilas G, Müller V. Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer. Br J Cancer. 2010 Sep 28;103(7):1048-56.

2010

Schröder C, Schumacher U, Müller V, Wirtz RM, Streichert T, Richter U, Wicklein D, Milde-Langosch K. The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells. Eur J Cancer. 2010 Jun;46(9):1650-60. Epub 2010 Mar 11.

2010

Witzel ID, Milde-Langosch K, Wirtz RM, Roth C, Ihnen M, Mahner S, Zu Eulenburg C, Jänicke F, Müller V. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome. J Cancer Res Clin Oncol. 2010 Mar 4.

2010

Croner RS, Wirtz R, Lausen B, Prokosch HU, Rödel C, Rödel F, Naschberger E, Wein A, Brückl WM, Hartmann A, Hohenberger W, Stürzl M – Prospective evaluation of predictive and prognostic molecular markers in colorectal carcinomas. J Clin Oncol 28, 2010 (suppl; abstr e14114) 

2010

Atmaca A, Steinmetz K, Pauligk C, Wirtz R, Homann N, Hofheinz R, Petry C, Altmannsberger HM, Jäger E, Al-Batran S – Validation of tumoral matrix-metalloproteinase-9 (MMP-9) mRNA expression as a molecular prognostic factor for metastatic gastroesophageal cancer . J Clin Oncol 28:15s, 2010 (suppl; abstr 4017)

2010

Psyrri D, Kronenwett R, Timotheadou E, Wirtz RM, Onyenadum A, Pentheroudakis GE, Papadimitriou CA, Razis E, Economopoulos T, Fountzilas G – Evaluation of the prognostic value of ube2c mrna levels in early breast cancer. J Clin Oncol 28:15s, 2010 (suppl; abstr 10570)

2009

Sinn B, Darb-Esfahani S, Wirtz R, Faggad A, Weichert W, Budczies J, Sehouli J, Braicu E, Dietel M, Denkert C – Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue – Virchows Arch. 2009 Nov 13.

2009

Pentheroudakis G, Kostadima L, Dova L, Georgiou I, Tzavaras T, Vartholomatos G, Wirtz RM, Fountzilas G, Malamou-Mitsi V, Pavlidis N – A twisted kiss: in vitro and in vivo evidence of genetic variation and suppressed transcription of the metastasis-suppressor gene KiSS1 in early breast cancer – Neoplasma. 2010;57(1):47-54.

2009

Faggad A, Budczies J, Tchernitsa O, Darb-Esfahani S, Sehouli J, Müller BM, Wirtz RM, Dhekerov R, Weichert W, Sinn B, Mucha C, Eldin Elwali N, Schäfer R, Dietel M, Denkert C – Prognostic significance of Dicer expression in ovarian cancer – Link to global microRNA changes and estrogen receptor expression – Journal of Pathology 2009

2009

Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A, Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D – MMP9 but not EGFR, MET, ERCC1, and P53 is associated with response to concomitant Radiotherapy, cetuximab and weekly Cisplatin in patients with locally advanced head and neck cancer – J of Oncology 2009

2009

Pentheroudakis G, Angouridakis N, Wirtz R, Nikolaou A, Kalogeras KT, Pavlidis N, Fountzilas G – Transcriptional Activity of Human Epidermal Growth Factor Receptor Family and Angiogenesis Effectors in Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma and Correlation with Patient Outcome – J Oncol. 2009;2009:854127. Epub 2009 Oct 7.

2009

Schröder C, Schumacher U, Fogel M, Feuerhake F, Müller V, Wirtz RM, Altevogt P, Krenkel S, Jännike F, Milde-Langosch K – Expression and prognostic value of L1-CAM in breast cancer. Oncology Reports 22: 1109-1117, 2009

2009

Zamagni C, Wirtz RM, De Iaco P, Veltrup E, Sehouli J, Dietel M, Rosati M, Denkert C, Martoni A – Estrogen receptor 1 mRNA predicts survival after neoadjuvant chemotherapy in ovarian cancer – determination by array and kinetic PCR in fresh tissue biopsies. Endocrine Relat Cancer 2009 Sep 11. [Epub ahead of print]

2009

Darb-Esfahani S, Wirtz RM, Sinn B, Budczies J, Noske A, Weichert W, Faggad A, Scharff S, Sehouli J, Oskay-Özcelik G, Martoni A, De Iaco P, Dietel M, Zamagni C, Denkert C – Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma – determination by kinetic PCR in formalin fixed tissue. Endocrine Relat Cancer 2009 Aug 12. [Epub ahead of print]

2009

Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, Nielsen FC, Weichert W, Buckendahl AC, Röske A, Müller B, Dietel M, Denkert C – IMP3 expression in human ovarian cancer is associated with improved survival. Int J Gynecol Pathol. 2009 May;28(3):203-10.

2009

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Noske A, Weichert W, Buckendahl AC, Budczies J, Müller BM, Elwali NE, Dietel M, Denkert C – Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology. 2009 May;54(6):657-66.

2009

Papaxoinis G, Pectasides D, Wirtz RM, Kotoula V, Papadimitriou C, Gogas H, Aravantinos G, Skarlos D, Kalogeras KT, Fountzilas G – Prognostic significance of PI3K mRNA expression in patients with operable high-risk breast cancer- J Clin Oncol 27:15s, 2009 (suppl; abstr 577)

2009

Pauligk C, Wirtz R, Steinmetz K, Hartmann JT, Homann N, Hofheinz RD, Petry C, Altmannsberger HM, Jäger E, Al-Batran S – Matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) mRNA expression in patients with metastatic gastric cancer receiving first-line chemotherapy – J Clin Oncol 27:15s, 2009 (suppl; abstr 4547)

2009

Kronenwett R, Stropp U, Briasoulis E, Gehrmann M, Razis E, Hennig G, Bafaloukos D, Wirtz RM, Economopoulos T, Fountzilas G – Utility of a multigene prognostic algorithm in combination with TP53 expression for prediction of benefit from adjuvant taxane-containing chemotherapy in node-positive breast cancer patients – J Clin Oncol 27:15s, 2009 (suppl; abstr 593)

2009

Wirtz RM – Die Krux mit der Bestimmung des Hormonrezeptors – Problems when determining the hormone receptor status – mammazoneMAG May 2009

2009

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Weichert W, Noske A, Budczies J, Müller BM, Buckendahl AC, Röske A, Eldin Elwali N, Dietel M, Denkert C. Topoisomerase II alpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol. 2009 Apr;22(4):579-88. Epub 2009 Mar 6.

2009

Gentner B, Wein A, Croner RS, Zeittraeger I, Wirtz RM, Roedel F, Dimmler A, Dorlaque L, Hohenberger W, Hahn EG, Brueckl WM — Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal cancers and their synchronous liver metastases – Anticancer Res 2009Jan; 29(1):67-74.

2008

Papadimitriou CA, Kalogeras KT, Wirtz RM, Briasoulis E, Hennig G, Vourli G, Stropp U, Gogas H, Galani E, Samantas E, Makatsoris T, Fountzilas G – ] Elevated mRNA expression of herstatin predicts poor outcome in patients with high-risk early breast cancer. A possible molecular predictor of treatment benefit in the context of a Hellenic cooperative oncology group trial. SABCS 2008 #6066

2008

Kronenwett R, Kalogeras KT, Stropp U, Weber K, Dafni U, Gehrmann M, Pectasides D, von Toerne C, Papakostas P, Wirtz RM, Fountzilas G – [6044] Prognostic algorithm identified in node-negative early breast cancer patients predicts outcome also in node-positive patients treated with adjuvant chemotherapy. SABCS 2008 #6044

2008

Ihnen M, Müller V, Wirtz RM, Milde-Langosch K, Witzel I, Lisboa BW, Jänicke F – Prediction of chemotherapy response in breast cancer by using a four-gene panel including osteopontin, activating leukocyte cell adhesion molecule (ALCAM), HER2 and estrogen receptor (ER). SABCS 2008 #2033

2008

Loibl S, Müller B, Roller M, Kronenwett R, Darb-Esfahani S, Komor M, von Toerne C, Wirtz R, von Minckwitz G, Denkert C – Local versus central HER2 immunohistochemistry correlates with kinetic RT-PCR but only central immunohistochemistry and RT-PCR predict pathological complete response: results from the neoadjuvant multicenter GeparTrio trial. SABCS 2008 #1070

2008

Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G – Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer. 2008 Dec 2;99(11):1775-85. Epub 2008 Nov 4.

2008

Al-Batran S, Pauligk C, Wirtz R, Steinmetz K, Probst S, Hartmann JT, Hofheinz R, Homann N, Altmannsberger HM, Petry C, Jäger E – The expression of the epidermal growth factor receptor (EGFR) and related molecules and their impact on survival in patients with metastatic gastric cancer receiving first-line chemotherapy: Results from the FLO versus FLP gastric cancer phase III trial of the AIO. Gastrointestinal Cancer Symposium 2008

2008

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. – Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat. 2008 Jul 31. [Epub ahead of print]

2008

Pauligk C, Wirtz RM, Steinmetz K, Probst S, Hartmann JT, Hofheinz R, Homann N, Altmannsberger HM, Petry C, Jäger E, Al-Batran S – The prognostic role of the epidermal growth factor receptor (EGFR) in patients with metastatic gastric cancer receiving first-line chemotherapy: Results from the FLO versus FLP gastric cancer phase III trial of the AIO. J Clin Oncol 26: 2008 (May 20 suppl; abstr 22033)

2008

Fountzilas G, Wirtz RM, Skarlos P, Dafni U, Pectasides D, Briasoulis E, Bafaloukos D, Xanthakis I, Gehrmann M, Kalogeras KT – Molecular classification based on only four genes identifies basal-like subtypes in high-risk breast cancer patients. J Clin Oncol 26: 2008 (May 20 suppl; abstr 11103)

2008

Zamagni C, Wirtz RM, Sinn B, De Iaco P, Darb-Esfahani S, Rosati M, Dietel M, Massari F, Martoni AA, Denkert C – Estrogen receptor 1 mRNA expression as a strong prognostic factor in epithelial ovarian cancer patients treated with chemotherapy in the adjuvant and neoadjuvant setting. J Clin Oncol 26: 2008 (May 20 suppl; abstr 16547)

2008

Papadimitriou C, Wirtz RM, Economopoulos T, Samantas E, Papakostas P, Gogas H, Razis E, Lianos E, Aravantinos G, Fountzilas G – Differential EGFR and VEGFR mRNA expression in two subtypes of basal-like breast cancer identified by molecular classification. J Clin Oncol 26: 2008 (May 20 suppl; abstr 22092)

2008

Al-Batran S, Wirtz RM, Pauligk C, Steinmetz K, Probst S, Hartmann JT, Hofheinz R, Altmannsberger HM, Petry C, Jäger E – Association of elevated matrix metalloproteinase-9 (MMP-9) mRNA expression levels with resistance to chemotherapy and survival in patients with metastatic gastric cancer receiving first-line chemotherapy: Results from the FLO versus FLP gastric cancer phase III trial of the AIO. J Clin Oncol 26: 2008 (May 20 suppl; abstr 4544)

2008

Brueckl WM, Schoeberl A, Wirtz RM, Murray S, Hahn EG, Wiest GH – Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). J Thorac Oncol. 2008 Mar;3(3):314-6.

2008

Ihnen M, Müller V, Wirtz RM, Schröder C, Krenkel S, Witzel I, Lisboa BW, Jänicke F, Milde-Langosch K – Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat. 2008 Jan 3; [Epub ahead of print]

2007

Niesporek S, Weichert W, Sinn B, Röske A, Noske A, Buckendahl AC, Wirtz R, Sehouli J, Koensgen D, Dietel M, Denkert C. – NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression. Verh Dtsch Ges Pathol. 2007;91:243-9. .

2007

Fountzilas G, Skarlos D, Wirtz RM, Dafni U, Stropp U, Pectasides D, Papakostas P, Markopoulos C, Karapanagiotis K, Polichronis A, Timotheadou E, Grimani I, Samantas E, Kosmidis P, Kalogeras KT – Prognostic value of both HER-2 and VEGF-A mRNA over-expression in primary tumors of high-risk breast cancer patients – SABCS 2007 #6007

2007

Lenhard MS, Wirtz RM, Hasmueller S, Rueckert S, Ditsch N, Ruehl I, Kahlert S, Bauerfeind I, Untch M, on Behalf of the Participating Centers – Relation of intratumoral B-cells and response to neoadjuvant chemotherapy. SABCS 2007 #2110

2007

Rueckert S, Wirtz R, Lenhard M, Hasmueller S, Ditsch N, Ruehl I, Kahlert S, Bauerfeind I, Untch M – Microtubule-associated protein tau is a marker of pathological complete response in Her-2/neu positive neoadjuvant treated breast cancer patients – SABCS 2007 #2016

2007

Wirtz R.M. – Molekularbiologische Ansätze für eine verbesserte Diagnostik und Selektion gezielter Therapieansätze – 27. Jahrestagung der deutschen Gesellschaft für Senologie – Lübeck Juni 2007 (Oral Presentation)

2007

Wirtz RM, Lenhard MS, Rückert S, Hasmüller S, Konecny G, Fasching P, Euting H, S. Claas S, Ditsch N, Rühl I, Bauerfeind I, Untch M – Determination of Her-2/neu status by semi-automated qRT-PCR in core needle biopsy FFPE tissues, correlation with standard IHC / FISH technology and response to neoadjuvant Trastuzumab-containing regimen (TECHNO-Trial) – AACC 2007

2007

Gehrmann M, Wirtz RM , von Törne C, Stropp U, Schmidt M – Concordance between protein and RNA tissue concentration of estrogen receptor alpha (ER) in fresh frozen as well as formalin fixed paraffin embedded breast tumors – AACC 2007

2007

Gehrmann M, Wirtz RM , von Törne C, Stropp U, Schmidt M – Breast cancer prognosis in node negative early breast cancer – AACC 2007

2007

Zamagni C, Wirtz RM, De Iaco P, Altimari A, Roth K, Rosati F, Rosati M, Massari F, Cacciari N, Martoni AA – Response to primary chemotherapy (CHT) in advanced epithelial ovarian cancer (EOC) patients (pts) and molecular characterization of CHT-resistant tumor cell populations: Findings from the Arianna 02 Project. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 16059

2007

Brueckl WM, Wirtz RM, Croner RS, Boxberger F, Papadopoulos T, Kirchner T, Hahn EG, Hohenberger W, Wein A – Evaluation of Spondin-1 as a predictive marker for palliative 5-FU based chemotherapy in metastatic colorectal cancer – Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4112.

2007

Briasoulis EC, Papamichael D, Tzachanis D, Christodoulou C, Samantas E, Razis E, Papakostas P, Bakoyiannis C, Wirtz RM, Kalogeras KT; – Predictive value of EGFR mRNA levels assessed by quantitative RT-PCR in primary tumors of patients treated with cetuximab for metastatic colorectal cancer – Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4121.

2007

Witzel I, Milde-Langosch K, Ihnen M, Lisboa B, Wirtz R, Müller V – Correlation between protein and RNA tissue concentration of biologic relevant factors in breast cancer – TRAFO 2007 #023

2007

Niesporek S., Weichert W., Sinn B., Röske A., Noske A., Buckendahl A.C., Wirtz R.M., Sehouli J., Koensgen D., Dietel M., Denkert C. – NF-κB subunit p65/RelA expression is an independent prognostic factor in human ovarian cancer and is linked to COX-2 overexpression in vivo and in vitro – AACR 2007 #2514

2007

Wirtz R.M. – Biomarker zur Prädiktion der Wirkung zielgerichteter Medikamente – 1. Forschungswerkstatt Onkologie der Bayer HealthCare AG – Köln 01 March 2007 (Oral Presentation and Publication). Der Onkologe 13 (2007), Suppl. 1, Springer Verlag.

2007

Linardou H., Fountzilas G., Wirtz R.M., Malamou-Mitsi V., Stropp U., Aravantinos G., Pectasides D., Gogas H., Grimani I., Koutras A., Dafni U., Hennig G., Skarlos D. and Kalogeras K.T. – Prognostic value of VEGF-A mRNA expression in primary tumors of high-risk breast cancer patients: a Hellenic Cooperative Oncology Group study. TAT 2007 P703.

2006

Lenhard M.S., Wirtz R.M., Rückert S., Hasmüller S., Ditsch N., Rühl I., Bauerfeind I., Untch M. – Correlation of quantitative Her-2/neu gene expression (TaqMan PCR) with standard immunohistochemistry and fluorescence in situ hybridization in core needle biopsies. SABCS 2006 #4009.

2006

Rueckert S., Wirtz R.M., Lenhard M., Ruehl I., Hasmueller S., Ditsch N., Bauerfeind I., Untch M. – Response prediction in neoadjuvant trastuzumab treated HER-2/neu-positive breast cancer by quantitative RT-PCR analysis of FFPE tissue. SABCS 2006 #3042.

2006

Ruehl I.M., Wirtz R.M., Lenhard M., Hasmueller S., Rueckert S., Ditsch N., Kahlert, Bauerfeind I., Untch M. – Significance of cyclin D1 expression and amplification status in paraffin-embedded tissue of Her2/neu positive breast cancer patients treated in a neoadjuvant trastuzumab-containing protocol (TECHNO-trial). SABCS 2006 #3027.

2006

Fountzilas G., Wirtz R.M., Skarlos D.V., Stropp U., Dafni U., Briasoulis E., Pectasides D., Gogas H., Kalofonos H.P., Papakostas P., Bafaloukos D., Economopoulos T., Aravantinos G., Kalogeras K.T., Dimopoulos M.A. – Prognostic value of DNA and RNA expression of HER-2 compared to that of HER-2 protein levels in primary tumors of high-risk breast cancer patients. SABCS 2006 #2032.

2006

Hasmueller S., Wirtz R.M., Lenhard M., Ditsch N., Rueckert S., Ruehl I., Bauerfeind I. and Untch M. – Amplification of Her2/neu and transcription levels of Her2/neu mRNA measured by RT-PCR in paraffin-embedded core-needle biopsies as predictive markers for response to neoadjuvant therapy with trastuzumab, epirubicin, cyclophosphamide and paclitaxel in early breast cancer (TECHNO-Trial). SABCS 2006 #1042.

2006

Wirtz R.M. – New Perspectives in the characterization and in the monitoring of ovarian cancer patients – Therapeutic Progresses and Perspectives in Ovarian Cancer – Bologna 01 Dec 2006 (Oral Presentation)

2006

Wirtz R.M. – Genetic alterations predicting the response of high-risk breast cancer patients to paclitaxel-based adjuvant chemotherapy – Breast Cancer: From Gene to Therapy – Thessaloniki 18 Nov 2006 (Oral Presentation)

2006

Kostadima L., Pentheroudakis G., Fountzilas G., Dimopoulos M., Pectasides D., Gogas H., Stropp U., Christodoulou C., Samantas E., Wirtz R., Hennig G., Bafaloukos D., Arapantoni P., Kalofonos H., Papakostas P., Economopoulos T., Bamias A., Pavlidis N. -Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Res Treat 2006; 100(2):161-7.

2006

Brueckl W.M., Wirtz R., Croner R.S., Boxberger F., Schuppert A., Meyer T., Papadopoulos T., Hahn E.G., Hohenberger W., Wein A. – Microarray based response prediction to palliative chemotherapy in metastatic colorectal carcinoma – HOX and MMP gene family members seem to be promising candidates. ESMO 2006 #860P.

2006

Brueckl W.M., Wirtz R., Croner R.S., Boxberger F., Gentner B., Munnes M., Schuppert A., Meyer T., Papadopoulos T., Hahn E.G., Hohenberger W., Wein A. – Hox- and MMP- gene family members are expressed in freshly frozen and paraffin embedded metastatic colorectal carcinoma – implication for response prediction to a palliative 5-FU containing chemotherapy. DKK 2006.

2006

Fountzilas G., Angouridakis N., Wirtz R.M., Claas S., Nikolaou A., Kalogeras K.T. – Prognostic value of VEGFC, HER2 and HER3 gene expression in recurrent squamous cell head and neck tumors -Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 5538.

2005

Brueckl W. M., Croner R. S., Hohenberger W., Munnes M., Wirtz R., Zeittraeger I., Meyer T., Papadopoulos T., Hahn E. G., Wein A. – Response prediction to a 5-Fluorouracil based first-line palliative chemotherapy for metastatic colorectal cancer by gene expression profiling of liver metastases using DNA microarrays- Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 3558.

2005

Fountzilas G., Stropp U., Razis E., Wirtz R., Skarlos D., Gogas H., Pavlidis N., Kalofonos H. P., Pectasides D., Dimopoulos A. M. – Genetic alterations predicting the response of high risk breast cancer patients to Taxol-based adjuvant chemotherapy- Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 9574.

2005

Wirtz R.M. – Molekulare Klassifizierung von Tumoren durch kombinierte DNA/RNA Analyse im Paraffingewebe – 25 th Annual Meeting of the German, Austrian an Suisse Breast Cancer Society – Stuttgart Sep 2005 (Oral Presentation)

2000

Wirtz R., Behrens J. and Birchmeier W. – Interaction of b-catenin with SWI/SNF factors. Keystone Symposia 2000.

1998

Behrens J., Jerchow B-A., Würtele M., Grimm J.,Asbrand C., Wirtz R., Kühl M., Wedlich D. and Birchmeier W. – Functional interaction of an axin homolg, conductin, with b-catenin, APC, and GSK3b. Science 1998; 280: 485-640.

1997

Brix K., Wirtz R. and Herzog V. – Paracrine interation between hepatocytes and macrophages after extrathyroidal proteolysis of thyroglobulin. Hepatology 1997; 26: 1232-1240.